Evaluation of serum resistin, visfatin and chemerin levels in patients with lung cancer and chronic obstructive pulmonary disease

Göktepe, Mustafa; Korkmaz, Celalettin; Zamanı, Adil; Demirbaş, Soner; Kılınç, İbrahim

doi:10.5152/turkthoracj.2019.19001

Cited by 2 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Study by Nigro et al, [32] indicated that NSCLC patients showed signi cantly higher serum resistin levels than healthy volunteers and they found that resistin might be involved in the pathophysiology of weight reduction in NSCLC patients. Our results disagree with [14] when who indicated that no signi cant correlation between the resistin level in the lung cancer and control groups. There aren't many studies looking into the connection between resistin and cancer.…”

Section: Discussioncontrasting

confidence: 99%

“…These results agree with results by Demiray et al, [11] who indicated that lung cancer Patients' serum resistin levels were noticeably elevated (6.3 ± 1.9) ng/ml at (P = .025) than the control group (4.4 ± 0.5) ng/ml. It was stated that tissue in ammation and organ failure were linked to this increase [14]. Study by Nigro et al, [32] indicated that NSCLC patients showed signi cantly higher serum resistin levels than healthy volunteers and they found that resistin might be involved in the pathophysiology of weight reduction in NSCLC patients.…”

Section: Discussionmentioning

confidence: 99%

“…Additionally, anti resistin antibody-treated mice have a lower incidence of lung tumors, indicating that resistin accelerates the progression of lung cancer. As a result, resistin may be a desirable target for the development of therapeutic approaches that target immune cells in the cancer microenvironment [14,15]. Irisin is an exercise-inducible myokine with a signi cant role in the regulation of body energy homeostasis [15,16].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Investigating the Role of Leptin, Resistin, and Irisin Levels as Prognostic Indicators in Iraqi Lung Cancer Patients

Hanoush,

Rashied,

Mohammed

2024

Preprint

View full text Add to dashboard Cite

Purpose Lung cancer is the most lethal malignancy and is often associated with a poor prognosis. However, limited studies have tested leptin, resistin, and irisin as biomarkers in lung cancers. Thus, this study aimed to determine whether irisin, resistin, and leptin could be useful biomarkers for lung cancer diagnosis. Methods The study is designed on 100 lung cancer patients at age rang (40–75) years, these patients divided in to (66) patients with non-small cell lung cancer (NSCLC) and (34) patients with small cell lung cancer (SCLC). For the purpose of comparison, (66) samples as control group with age range (40–70) years. Each patient and control had five milliliters of blood taken. Then the sera used to estimate the Leptin, Resistin, and Irisin by using ELISA technique. Results The results indicates the mean of Leptin was significant increase in NSCLC and SCLC groups (10.71 ± 0.30 and 10.13 ± 0.51)ng/ml respectively, in contrast to the control group (8.26 ± 0.47) ng/ml. The mean of Irisin significant increase in SCLC group (5.86 ± 0.13) pg/ml and NSCLC group(5.08 ± 0.09)pg/ml in contrast to the control group (4.13 ± 0.09) pg/ml. Resistin had been significant increase in SCLC group (7.25 ± 0.38)ng/ml followed by NSCLC group (6.35 ± 0.13)ng/ml compared with control group (3.96 ± 0.17) ng/ml. Conclusion The higher levels of leptin in NSCLC patients could serve as prognostic marker for NSCLC. The variations in Resistin and Irisin levels across different stages of lung cancer suggest that they might be useful in predicting the prognosis of lung cancer.

show abstract

Section: Discussioncontrasting

confidence: 99%